BioCentury

7:00 AM GMT, May 4, 2009
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Product Development

To the Rescue

Hypoglycemia is the most common side effect of insulin treatment and can result in seizures, unconsciousness and death. Administering glucagon reverses hypoglycemia by facilitating the release of glucose into the bloodstream. Yet, according to Enject Inc., only 900,000 glucagon rescue kits are sold annually in the U.S., where there are 1.4 million Type I diabetics who should have at least one rescue product on hand.

Moreover, the two glucagon rescue products marketed in the U.S. have a total

Read the full 773 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.